– UK, Guildford – Ergomed plc (LON: ERGO), a company focused on providing specialised services to the pharmaceutical industry, today announced the appointment of John Dawson, CBE to its Board as an Independent Non-Executive Director.
John Dawson will also join the Audit Committee as Chair.
About John Dawson
John Dawson is a highly experienced and globally respected figure in the healthcare sector. Most recently, he was CEO of Oxford Biomedica (LON: OXB) where, during his 13-year tenure, the business grew into a global market leader in viral vector technologies for cell and gene therapy, delivered multiple high-value partnerships, and successfully manufactured the life-saving Oxford/AstraZeneca COVID-19 vaccine. Under Mr. Dawson’s leadership, Oxford Biomedica’s success resulted in it entering the FTSE 250 index in 2020. Subsequently, in the New Year Honours List this year, he was awarded a CBE for services to UK life science, in recognition of the unprecedented speed and success at which Oxford Biomedica delivered the COVID-19 vaccine.
Prior to Oxford Biomedica, Mr. Dawson held various senior executive roles including at Cephalon Pharmaceuticals where for most of his tenure he was Managing Director for Europe. Prior to this, he served as the Financial Director for Serono before its acquisition by Merck. Mr. Dawson holds a BSc in Mathematics from Swansea University and is a Chartered Accountant.
John Dawson, CBE, said: “Ergomed is fast becoming a leading global pharmaceutical services provider, which has seen exceptional growth over the past few years, and which remains at a very exciting stage in its development. I look forward to working closely with the Board and Senior Management Team as we continue to build upon this momentum.”
About Ergomed plc
Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed’s fast-growing services business includes an industry-leading suite of specialist pharmacovigilance solutions, integrated under the PrimeVigilance brand, a full range of high-quality clinical research and trial management services under the Ergomed brand and mission-critical regulatory compliance and consulting services under the ADAMAS brand.
For more information: https://ergomedplc.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.